In prostate cancer cells, ciglitazone and its analogue reduce prostate-specific antigen (PSA) secretion with and without a decrease in the expression of androgen receptor (AR), independent of PPAR-γ activation. The gene discussed is PPARG; the disease is prostate carcinoma.